Get started
Author

M. Cavo

Observed names: Cavo, Michele, M Cavo, Michel Cavo, Michele Cavo
OpenAlex ID: A5079830536
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
2018 · Mohamad Mohty, Mohamad Mohty, et al. · Clinical Lymphoma Myeloma & Leukemia · 82
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival
2017 · M C Fontana, G Marconi, et al. · Leukemia · 9
PDF
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis
2026 · Efstathios Kastritis, Giovanni Palladini, et al. · Blood · 4
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
2024 · Meletios A. Dimopoulos, Pieter Sonneveld, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights
2026 · Enrica Manzato, Michele Puppi, et al. · Blood Advances · 1
Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma
2026 · Francesco Sparano, Gianluca Gaidano, et al. · JCO Oncology Practice · 1
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
2026 · Nizar Bahlis, Thierry Facon, et al. · Blood Advances · 1
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
2026 · Katarina Uttervall, Martin K. Kortum, et al. · Haematologica · 1
PDF
Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies
2026 · Michele Cavo, Sara Bringhen, et al. · Frontiers in Oncology · 1
PDF
KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel
2026 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Transplantation and Cellular Therapy · 1
MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM-8 Long-Term Responder Analysis
2026 · Meletios A Dimopoulos, Meral Beksaç, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM‐8 Long‐Term Responder Analysis
2026 · Meletios A Dimopoulos, Meral Beksaç, et al. · Clinical Lymphoma Myeloma & Leukemia
Real‐World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey
2026 · Francesca Fazio, Alfonso Piciocchi, et al. · eJHaem
Erratum to: “Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial”
2026 · Salomon Manier, Meletios-Athanasios Dimopoulos, et al. · Haematologica
Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.
2026 · Meletios A. Dimopoulos, Meral Beksaç, et al. · Journal of Clinical Oncology
An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma
2026 · Paolo Corradini, Pellegrino Musto, et al. · Leukemia Research
P46 | Circulating Plasma Cells as a Dynamic Biomarker in Multiple Myeloma Patients Receiving Car-t and Bispecific Antibody Therapy
2026 · I. Vigliotta, A. Varacalli, et al. · Haematologica
PDF
P16 | INTEGRATED p53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA
2026 · E. Borsi, A. Vitale, et al. · Haematologica
PDF
P12 | Subcutaneous Daratumumab (dara) + Bortezomib/lenalidomide/dexamethasone With Dara + Lenalidomide Maintenance in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma: Analysis of Sustained Minimal Residual Disease Negative
2026 · P. Sonneveld, Ph. Moreau, et al. · Haematologica
PDF
P18 | Monoclonal and Polyclonal Circulating Plasma Cells Are Associated With Disease Dissemination in Multiple Myeloma
2026 · I. Vigliotta, A. Varacalli, et al. · Haematologica
PDF
P53 | Nationwide Experience With Standard of Care Idecabtagene Vicleucel in Relapsed/refractory Multiple Myeloma: a Real World Study on Behalf of the Gruppo Italiano Malattie Ematologiche Dell'adulto Foundation
2026 · M. Puppi, M. Pennisi, et al. · Haematologica
PDF
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone
2026 · Carmine Liberatore, Alfonso Piciocchi, et al. · Haematologica
PDF
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
2026 · Stefania Oliva, Marina Martello, et al. · Cancer Medicine
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe
2026 · Michele Cavo, Fredrik Schjesvold, et al. · Haematologica
PDF
MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
2024 · Pieter Sonneveld, Philippe Moreau, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 36
Citation count: 186
H-index: 4
I10-index: 2
Year
Topic
Type